Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fig. 2. GPC3 expression in normal and tumor tissues.

Published byTeguh Agusalim Modified over 5 years ago

Similar presentations

Presentation on theme: "Fig. 2. GPC3 expression in normal and tumor tissues."— Presentation transcript:

1 Fig. 2. GPC3 expression in normal and tumor tissues.
GPC3 expression in normal and tumor tissues. IHC analysis of an anti-GPC3 mouse antibody (mGC33) in a multi-tissue array. Representative photomicrographs of GPC3 staining in tumor and normal tissues are shown. Cytoplasmic H-scores are indicated in parentheses. H-scores were calculated as values between 0 and 300, defined as [1 × (percentage of cells staining at 1+ intensity) + 2 × (percentage of cells staining at 2+ intensity) + 3 × (percentage of cells staining at 3+ intensity) = H-score]. Photos were taken using a 20× objective lens. Takahiro Ishiguro et al., Sci Transl Med 2017;9:eaal4291 Published by AAAS

Download ppt "Fig. 2. GPC3 expression in normal and tumor tissues."

Similar presentations

Fig. 1. TP is highly expressed in myeloma.

Fig. 1. TP is highly expressed in myeloma.
Fig. 8. Recurrent copy number amplification of BRD4 gene was observed across common cancers. Recurrent copy number amplification of BRD4 gene was observed.

Fig. 8. Recurrent copy number amplification of BRD4 gene was observed across common cancers. Recurrent copy number amplification of BRD4 gene was observed.
Fig. 2. Effects of AZD4785 on proliferation and MAPK pathway signaling in KRAS mutant and wild-type cancer cells in vitro. Effects of AZD4785 on proliferation.

Fig. 2. Effects of AZD4785 on proliferation and MAPK pathway signaling in KRAS mutant and wild-type cancer cells in vitro. Effects of AZD4785 on proliferation.
Fig. 4. Primary human metastatic melanomas contain CCL21-expressing LECs, and expression of VEGFC positively correlates with hallmarks of tumor inflammation.

Fig. 4. Primary human metastatic melanomas contain CCL21-expressing LECs, and expression of VEGFC positively correlates with hallmarks of tumor inflammation.
Fig. 1. Generation of ERY974. Generation of ERY974. (A) Schematic illustration of ERY974 structure and the introduced mutations. The two Fab arms share.

Fig. 1. Generation of ERY974. Generation of ERY974. (A) Schematic illustration of ERY974 structure and the introduced mutations. The two Fab arms share.
Fig. 1. Potent and selective down-regulation of KRAS mRNA and protein by AZD4785 in vitro and in vivo. Potent and selective down-regulation of KRAS mRNA.

Fig. 1. Potent and selective down-regulation of KRAS mRNA and protein by AZD4785 in vitro and in vivo. Potent and selective down-regulation of KRAS mRNA.
Fig. 1. The cell-intrinsic fibroblast circadian proteome contains numerous cytoskeletal regulators. The cell-intrinsic fibroblast circadian proteome contains.

Fig. 1. The cell-intrinsic fibroblast circadian proteome contains numerous cytoskeletal regulators. The cell-intrinsic fibroblast circadian proteome contains.
Fig. 5. Circulating PPi concentration does not correlate with severity of calcification phenotype in mice. Circulating PPi concentration does not correlate.

Fig. 5. Circulating PPi concentration does not correlate with severity of calcification phenotype in mice. Circulating PPi concentration does not correlate.
Fig. 3 Urinary LAM concentration predicted pulmonary TB and correlated to mycobacterial burden and weight loss. Urinary LAM concentration predicted pulmonary.

Fig. 3 Urinary LAM concentration predicted pulmonary TB and correlated to mycobacterial burden and weight loss. Urinary LAM concentration predicted pulmonary.
Fig. 4. Intramuscular injection of AAV9-Cas9/sgRNA-51 corrects dystrophin expression. Intramuscular injection of AAV9-Cas9/sgRNA-51 corrects dystrophin.

Fig. 4. Intramuscular injection of AAV9-Cas9/sgRNA-51 corrects dystrophin expression. Intramuscular injection of AAV9-Cas9/sgRNA-51 corrects dystrophin.
Fig. 4. NASH-driven fibrosis is partly TGF-β–dependent.

Fig. 4. NASH-driven fibrosis is partly TGF-β–dependent.
Fig. 3. Obese IFN-γ−/− mice develop accelerated NAFLD with fibrosis.

Fig. 3. Obese IFN-γ−/− mice develop accelerated NAFLD with fibrosis.
IHC staining of FFPE esophageal tissues in tissue microarrays (×20).

IHC staining of FFPE esophageal tissues in tissue microarrays (×20).
Fig. 2. In vitro profiling of tEV markers on cell line–derived EVs.

Fig. 2. In vitro profiling of tEV markers on cell line–derived EVs.
Fig. 2 TLR8 is aberrantly expressed on pDCs from SSc patients.

Fig. 2 TLR8 is aberrantly expressed on pDCs from SSc patients.
Fig. 6 Bimodal treatment results in reduced tinnitus loudness and reduced TFI scores in human patients. Bimodal treatment results in reduced tinnitus loudness.

Fig. 6 Bimodal treatment results in reduced tinnitus loudness and reduced TFI scores in human patients. Bimodal treatment results in reduced tinnitus loudness.
Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.

Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.
Maraba treatment sensitizes 4T1 tumors to immune checkpoint blockade

Maraba treatment sensitizes 4T1 tumors to immune checkpoint blockade
Bio-AMS enhances the activity of rifampicin and ethambutol in vitro

Bio-AMS enhances the activity of rifampicin and ethambutol in vitro
Fig. 5. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic mice. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic.

Fig. 5. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic mice. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic.

Similar presentations

Ads by Google